Having shown the enhanced activity of the 10,000-fold attenuated IL-18 antibody fusion in vitro, we investigated in vivo anti-tumor activity of three IL-18mut variants fused to a single armed RMP1–14 characterized by attenuations of 100-fold up to 1,000,000-fold. This evidence concerns the gene IL18 and neoplasm.